Brief: Polypeptide Updates FY 2026 Guidance To 25-30% Revenue Growth, High-Teens Ebitda Margin
19/07/2026 23:50
BRIEF-Polypeptide Updates FY 2026 Guidance To 25-30% Revenue Growth, High-Teens Ebitda Margin July 19 (Reuters) - PolyPeptide Group AG PPGN.S:
POLYPEPTIDE GROUP: SAMSUNG BIOLOGICS ANNOUNCES TENDER OFFER TO ACQUIRE POLYPEPTIDE GROUP AG FOR CHF 44.31 PER SHARE
POLYPEPTIDE GROUP AG - UPDATES FY 2026 GUIDANCE TO 25-30% REVENUE GROWTH, HIGH-TEENS EBITDA MARGIN
POLYPEPTIDE GROUP AG - H1 2026 REVENUE EUR 236.6 MILLION, UP 41.6% YEAR-ON-YEAR
Source text: ID:nEQ9cX1X2a
Further company coverage: PPGN.S
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SAMSUNG BIOLOGICS
See all newsSouth Korean shares log 6-month closing low as chipmakers fall on profit-taking
South Korean shares fall on profit taking; BOK in focus
South Korean shares post biggest gain in 6 weeks as chipmakers rebound
South Korean shares fall nearly 3% as AI concerns hit chipmakers
South Korean shares start week lower on AI worries